Today, BioPortos Board of directors appointed Peter Mørch Eriksen as new CEO of the company.
Thea Olesen resigns her position as CEO of the company and the subsidiary BioPorto Diagnostics A/S. Thea Olesen has served in management positions since the start of the company. She has contributed to the listing of BioPorto in 2004 and as CEO, she has led the successful development and launch of the kidney injury marker, The NGAL Test™. During Thea Olesen’s leadership, BioPorto has marked itself within renal diagnostics and helped improve the possibilities of diagnosis and thus treatment of acute kidney injury.
The company’s new CEO, Peter Mørch Eriksen, has more than 15 years of experience within medtech/life science in Denmark and abroad. Peter Mørch Eriksen was previously CEO of Sense A/S and prior to this, he held the position as VP of Medtronic in both the USA and Denmark. From these positions Peter Mørch Eriksen brings extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. Peter Mørch Eriksen has an accounting background supplemented with courses in management and is also Chairman of MTIC, member of Lund University Advisory Board, and Director of PMEconsult.
Chairman of the board of directors Thomas Magnussen says: “Thea, with her hard work and vision for the company has created a favourable position in an emerging market, and we thank and recognize her for this effort. At this point we must ensure that we take full advantage of our position and that requires a more commercial profile that we have found in Peter Mørch Eriksen. Besides helping to implement the forthcoming rights issue, Peter’s tasks are to realize the revenue opportunities and ensure the company’s future success. We look forward to working with Peter.”
For further information please contact:
Thomas Magnussen, Chairman of the board
Christina Thomsen, Investor Relations
Tel. +45 45 29 00 00, mail investor@bioporto.com
